Berta Moritz

858 total citations
20 papers, 500 citations indexed

About

Berta Moritz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Berta Moritz has authored 20 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Berta Moritz's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). Berta Moritz is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). Berta Moritz collaborates with scholars based in Germany, Switzerland and Netherlands. Berta Moritz's co-authors include Ronald de Groot, Paul Mulder, Jan A. Hazelzet, Koen F. M. Joosten, Werner Engl, C. Erik Hack, Ester D. de Kleijn, Ulrich Jaehde, Stefanie Kraff and Gary Feiss and has published in prestigious journals such as Journal of Clinical Oncology, Critical Care Medicine and Annals of Oncology.

In The Last Decade

Berta Moritz

20 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Berta Moritz Germany	8	182	144	112	82	70	20	500
Patrick J. Kiel United States	14	144 0.8×	145 1.0×	52 0.5×	81 1.0×	98 1.4×	39	613
Sophie Séronie-Vivien France	11	157 0.9×	49 0.3×	132 1.2×	178 2.2×	115 1.6×	23	744
Somedeb Ball United States	15	290 1.6×	62 0.4×	162 1.4×	160 2.0×	145 2.1×	99	802
Hada C. Macher Spain	13	74 0.4×	152 1.1×	56 0.5×	31 0.4×	133 1.9×	31	567
Jin Woo Kim South Korea	16	126 0.7×	90 0.6×	368 3.3×	22 0.3×	100 1.4×	38	608
Özlem Harmankaya Türkiye	12	75 0.4×	61 0.4×	49 0.4×	22 0.3×	68 1.0×	41	454
M Espirito Santo Israel	8	152 0.8×	272 1.9×	109 1.0×	59 0.7×	38 0.5×	15	582
Tomoya Shimokata Japan	18	238 1.3×	46 0.3×	330 2.9×	29 0.4×	134 1.9×	57	785
Ceri Hirst United Kingdom	15	71 0.4×	62 0.4×	74 0.7×	147 1.8×	41 0.6×	28	573
Beate Luxembourg Germany	17	56 0.3×	88 0.6×	43 0.4×	293 3.6×	62 0.9×	33	706

Countries citing papers authored by Berta Moritz

Since Specialization

Citations

This map shows the geographic impact of Berta Moritz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berta Moritz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berta Moritz more than expected).

Fields of papers citing papers by Berta Moritz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berta Moritz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berta Moritz. The network helps show where Berta Moritz may publish in the future.

Co-authorship network of co-authors of Berta Moritz

This figure shows the co-authorship network connecting the top 25 collaborators of Berta Moritz. A scholar is included among the top collaborators of Berta Moritz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Berta Moritz. Berta Moritz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Kanefendt, Friederike, JJ Swen, F. Sörgel, et al.. (2017). Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer. CPT Pharmacometrics & Systems Pharmacology. 6(9). 604–613. 19 indexed citations

2.

Salamone, Salvatore J., Ulrich Jaehde, Lothar Mueller, et al.. (2017). Prospective, multi-center study of 5-fluorouracil (5-FU) therapeutic drug management (TDM) in metastatic colorectal cancer (mCRC) patients treated in routine clinical practice.. Journal of Clinical Oncology. 35(4_suppl). 650–650. 3 indexed citations

3.

Wilhelm, Martin, Lothar Mueller, Michael Craig Miller, et al.. (2016). Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. Clinical Colorectal Cancer. 15(4). 381–388. 54 indexed citations

4.

Pawel, Joachim von, Stefanie Kraff, Wilfried Eberhardt, et al.. (2016). Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced Non-Small Cell Lung Cancer (NSCLC) patient. Pneumologie. 70(S 01). 4 indexed citations

5.

Kunzmann, Volker, Michael Craig Miller, Stefan Holdenrieder, et al.. (2015). A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens.. Journal of Clinical Oncology. 33(15_suppl). 3542–3542. 3 indexed citations

6.

Pawel, Joachim von, Jeng‐Sen Tseng, Mircea Dediu, et al.. (2015). Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs). Pneumologie. 69(S 01). 3 indexed citations

7.

Joerger, Markus, Joachim von Pawel, Stefanie Kraff, et al.. (2015). Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient.. Journal of Clinical Oncology. 33(15_suppl). 8051–8051. 3 indexed citations

8.

Bergmann, Lars, Viktor Grünwald, Luise Maute, et al.. (2015). 2617 A Prospective Randomized Phase-II Trial with Temsirolimus vs. Sunitinib in non-clear Renal Cell Carcinoma. A Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and Interdisciplinary Renal Cell Carcinoma Group of the German Cancer Society (IAGN). European Journal of Cancer. 51. S517–S517. 3 indexed citations

9.

Bergmann, Lothar, Luise Maute, Gerhard Heil, et al.. (2014). A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. European Journal of Cancer. 51(1). 27–36. 51 indexed citations

10.

Mross, K., M. E. Scheulen, Dirk Strumberg, et al.. (2014). FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases â a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. International Journal of Clinical Pharmacology and Therapeutics. 52(8). 642–652. 6 indexed citations

11.

Paz‐Ares, Luis, Joachim von Pawel, Berta Moritz, et al.. (2014). Phase (Ph) 3 Study of Patritumab (P) Plus Erlotinib (E) in Egfr Wild-Type Subjects with Advanced Non–Small Cell Lung Cancer (Nsclc). Annals of Oncology. 25. iv470–iv470. 4 indexed citations

12.

Pawel, Joachim von, Jennifer Tseng, Mircea Dediu, et al.. (2014). Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs).. Journal of Clinical Oncology. 32(15_suppl). 8045–8045. 19 indexed citations

13.

Richly, Heike, Luise Maute, Gerhard Heil, et al.. (2013). Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.. Journal of Clinical Oncology. 31(15_suppl). 4035–4035. 7 indexed citations

14.

Joerger, Markus, Stefanie Kraff, Alwin D. R. Huitema, et al.. (2012). Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring. Clinical Pharmacokinetics. 51(9). 607–617. 46 indexed citations

15.

Joerger, Markus, Stefanie Kraff, Alwin D. R. Huitema, et al.. (2012). Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring. Clinical Pharmacokinetics. 51(9). 607–617. 1 indexed citations

16.

Mross, K., Martin Büchert, Ulrike Fasol, et al.. (2011). A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment - a study of the CESAR central european society for anticancer drug research - EWIV**. 4 indexed citations

17.

Mross, K., Martin Büchert, Ulrike Fasol, et al.. (2011). A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.. PubMed. 49(1). 96–8. 6 indexed citations

18.

Kleijn, Ester D. de, Ronald de Groot, C. Erik Hack, et al.. (2003). Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Critical Care Medicine. 31(6). 1839–1847. 242 indexed citations

19.

Váradi, Katalin, Berta Moritz, Heinrich Lang, et al.. (1995). A chromogenic assay for activated protein C resistance. British Journal of Haematology. 90(4). 884–891. 17 indexed citations

20.

Moritz, Berta, et al.. (1995). International Normalized Ratio (INR) – Proficiency Tests by ÖQUASTA for the Prothrombin Time. Hämostaseologie. 15(1). 41–48. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact